Two first-in-class ADPKD drugs presented their first human data at ASN Kidney Week 2026 in Denver.
AZD1613 (AstraZeneca) is a human monoclonal antibody against PAPPA, an enzyme that frees growth-promoting IGF-1 inside cystic kidneys by cleaving its binding protein IGFBP4. In 64 healthy volunteers across eight single-dose cohorts (NCT06995820), there were no serious adverse events or discontinuations and no clinically significant lab, vital-sign or ECG changes. Exposure rose in proportion to dose, and cleaved IGFBP4 — the direct readout of PAPPA activity — stayed suppressed for more than 100 days. That sustained target inhibition is what the ongoing multiple-dose study in ADPKD patients (PIONEER-PKD) is building on.
PYC-003 (PYC Therapeutics) is an antisense drug that blocks microRNA-17 from binding PKD1 mRNA, aiming to raise production of polycystin-1, the protein that is deficient in ADPKD. In an oral presentation, PYC reported single doses up to 2.4 mg/kg in 18 ADPKD patients in the PINACLE-1 trial (NCT06714006), with no treatment-related serious adverse events or discontinuations. Urinary polycystin-1 showed a directional increase, and early kidney volume changes were described as directionally encouraging but needing confirmation in the repeat-dose cohorts now underway. PYC expects multiple-dose and extension data in 2027 and is describing a registrational Phase 2/3 trial as the next step.
Both readouts are early and exploratory, but they show two genuinely new approaches clearing the first hurdle. AbbVie/Calico's ANCHOR trial of ABBV-CLS-628, another PAPPA antibody, also presented its design: 240 patients at 72 sites in 12 countries, with no efficacy data yet.